Watson Pharmaceuticals
To see an up-to date selection of historical analyses and insights on
Watson Pharmaceuticals,
visit our
new, dynamically updated Company Summary report pages for Watson Pharmaceuticals.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Watson Pharmaceuticals are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Watson Pharmaceuticals,
or on any other Company covered by EvaluatePharma® Contact Us today.
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| Watson Confirms Filing of FDA Application for Generic Lidoderm(R)
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Watson Files FDA Application for Generic LoSeasonique(R)
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Watson Files FDA Application for Generic Nuvigil(R)
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| New Published Data Demonstrate Long-Term Safety, Efficacy and Tolerability of Watson's RAPAFLO(R) (silodosin) for Benign Prostatic Hyperplasia (BPH) Symptom Relief
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| New Data Suggest that GELNIQUE(R) (oxybutynin chloride) gel 10% Does Not Impact Cognition among Healthy Older Adults
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Watson Files FDA Application for Generic Mucinex(R) D
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Watson Launches GELNIQUE(TM) (Oxybutynin Chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| FDA Approves ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
|
(Takeda)
|
(Invalid Date)
|
| RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Presented Data Confirm That RAPAFLO(TM) (Silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| New Data Presented at AUA's Annual Conference Prove GELNIQUE(TM) (Oxybutynin Chloride) 10% Gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Watson Files FDA Applications for Generic Mucinex(R)
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| SILODOSIN Launched (Brand Name in Japan: Urief®) in the US
|
(Kissei Pharmaceutical)
|
(Invalid Date)
|
| Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| New, Published GELNIQUE Data Show Efficacy, Convenience and Excellent Tolerability
|
(Watson Pharmaceuticals)
|
(Invalid Date)
|
| Paladin Files New Drug Submission for TRELSTAR(R) 6 Month
|
(Paladin Labs)
|
(Invalid Date)
|
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
